Navigation Links
AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Date:11/27/2007

ma, Inc. ("APPY") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward- looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including the ability to successfully complete the development of, obtain FDA clearance for and generate revenues from the appendicitis test and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.

For more information contact:

AspenBio Pharma, Inc.

Gregory Pusey, Chairman

Tel 303-722-4008

Investor Relations:

Liolios Group, Inc.

Scott Liolios or Ron Both

Tel 949-574-3860


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AspenBio Pharma Reports Second Quarter 2007 Results
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
4. AspenBio Pharma to Present the Edgewater Research Investor Conference
5. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... May 5 NorthPoint Domain, an IC Sciences,company, ... Vascular,Associates at NYU Langone Medical Center to develop ... specialty care delivery.,Based on a shared commitment to ... need to provide clinicians with new,tools to inform, ...
... DuPont (NYSE: DD ),today announced the ... to its external Biotechnology Advisory Panel. They join ... bring diverse viewpoints to the,broad area of biotechnology ... Pental is a professor of Genetics and ...
... PLC ) announced today that it expects to release to ... March 31, 2008 before the,market opens on Thursday, May 15, ... those results at 11:00 a.m. ET on that same day., ... (800) 638-4930 or (617),614-3944 (for international participants) at least five ...
Cached Biology Technology:NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 2NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 3DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members 2DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members 3PLC Systems to Host First Quarter Conference Call on May 15, 2008 2
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... , July 1, 2014 Smart technology ... for convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay ... GOOG ), Apple Inc. (NASDAQ: AAPL ), ... (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... announce that the second series of 30 second spots on ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... . Air in the United States could ... laboratory researchers expect will help in the development of ... Vehicle Systems Integration Laboratory provides unprecedented capabilities that will ... transmissions, and other drivetrain and emissions components. The payoff ...
... the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has ... protein linked to stem cell-like behavior in terminal-stage chronic ... that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , is ...
... WHAT: Conference on Lasers and Electro-Optics (CLEO: ... 14 (Exhibits open June 11-13) at the San Jose Convention ... 2013, the Conference on Lasers and Electro-Optics, is the premier ... to photonic applications and products. CLEO: 2013 builds on the ...
Cached Biology News:June 2013 story tips 2June 2013 story tips 3June 2013 story tips 4Singapore research team identifies new drug target in deadly form of leukemia 2'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 2'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 3'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 4'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 5
... System is ideal for developing single and ... system contains the new, improved, and user ... user can design specific templates for commercial ... fully integrated graphing and data regression capabilities; ...
... Sweep- based acquision and analysis ... response type applications. Contains powerful ... flexible analysis functions including automated ... plotting. Also includes many electrophysiology ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: